A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
Esophageal Squamous Cell Carcinoma (ESCC)
DRUG: Cisplatin|DRUG: Oxaliplatin|DRUG: Fluorouracil (5-FU)|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Tislelizumab|DRUG: Placebo
Overall Survival (OS), OS is defined as the time from the date of randomization until the date of death due to any cause, Up to approximately 3 years and 2 months (as of primary analysis data cut-off date of 28FEB2022)
Progression-Free Survival (PFS), PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first, Approximately 40 months from date of the first participant randomization|Objective Response Rate (ORR), ORR is defined as the proportion of participants whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1, Approximately 40 months from date of the first participant randomization|Overall Survival (OS) in the PD-L1 Score â‰¥ 10% Subgroup, OS is defined as the time from the date of randomization until the date of death due to any cause, Approximately 40 months from date of the first participant randomization|Duration of Response (DOR), DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever comes first, Approximately 40 months from date of the first participant randomization|Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using European Quality of Life-Core 30 Questionnaire Index (EORTC QLQ-C30), Approximately 40 months from date of the first participant randomization|Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Esophageal Cancer Specific Module (EORTC QLQ-OES18), Approximately 40 months from date of the first participant randomization|Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using the Generic Health State Instrument European Quality of Life-5 Dimensions (EuroQol 5D EQ-5D-5L), Approximately 40 months from date of the first participant randomization|Number of Participants Experiencing Adverse Events (AEs), Approximately 40 months from date of the first participant randomization
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).